 TEL AVIV, Israel, March 11, 2021 GLOBE NEWSWIRE -- Purple Biotech Ltd. Purple Biotech , or the Company NASDAQTASE: PPBT, a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that additional preclinical data supporting the mechanism of action of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS12 and STAT3, will be presented in a poster at the American Association of Cancer Research AACR 2021 Annual Meeting, taking place in virtual format, on April 10-15 and May 17-21, 2021. These updated data expand on the previously reported results generated from the Companys collaboration with Professor Ido Wolf, Head of the Oncology Division, Tel Aviv Sourasky Medical Center, and will be highlighted in a presentation titled, Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2. 